No, diabetes-related retinopathy is not reversible. But you can slow down progression or stop it from getting worse through diabetes management, eye injections, laser treatment, and more. Diabetic ...

Patients with type 1 diabetes have over four times the risk for glaucoma and ocular hypertension if they also have diabetic ...

Aims To evaluate whether predominantly peripheral lesions (PPLs) and other imaging biomarkers on ultra-widefield (UWF) ...

The five human senses include sight, hearing, smell, taste, and touch. While each of these matter for different reasons, they aren't perceived as being equal. For instance, according to a YouGov ...

I learned I had diabetic retinopathy in 2004. Unfortunately, my diagnosis came a little too late, and I lost most of the vision in my right eye. Today, when I do advocacy work, I stress how important ...

This story is part of a series on the current progression in Regenerative Medicine. This piece is part of a series dedicated to the eye and improvements in restoring vision. This piece also marks part ...

RA tirzepatide for type 2 diabetes mellitus (T2DM) therapy has lower odds of instigating retinal complications.

The prevalence of vision-threatening retinopathy in people with diabetes has increased exponentially in the past decade, most acutely among younger adults and Hispanic and Black populations, an ...

If you have diabetes, you should already be aware of the danger of diabetic retinopathy. This unfortunately common complication can lead to eyesight issues and, in extreme cases, even blindness. It ...

STOCKHOLM — At the American Society of Retina Specialists (ASRS) 2024 Annual Meeting, researchers discussed how insights into potential risk factors and new treatments could improve outcomes for ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. About 7% of youths with type 2 diabetes have diabetic ...

Kodiak Sciences Inc. recently reported a first-quarter 2026 net loss of US$58.16 million while highlighting positive Phase 3 GLOW2 results for Zenkuda in diabetic retinopathy and advancing multiple ...